Sysorex Global Holdings Corp. (SYRX)

[monda2frida]

News:

Sysorex announces latest in series of IT engagements with Fortune 500 biopharmaceutical firm

$1.2 million engagement will have Sysorex provide critical IT infrastructure systems and services for BioPharma leader

PALO ALTO, Calif. – Big data analytics and solutions provider Sysorex (NASDAQ: SYRX) today announced it has once again been engaged by a Fortune 500 biopharmaceutical research and development firm to provide critical data infrastructure migration and upgrade services. The project, valued at approximately $1.2 million, is the latest in a series of projects Sysorex has completed for the customer this year. All totaled, Sysorex has provided more than $3 million in IT systems and services for the customer in 2015.

“I think it speaks to both the quality and differentiation of Sysorex’s products and services that a Fortune 500 company has made multiple and successive orders,” said Sysorex CEO, Nadir Ali. “I’m very proud of our employees and the quality of work they deliver.”

Sysorex expects the new engagement to be completed by the end of 2015.

About Sysorex
Sysorex develops the systems and solutions that power the data-driven enterprise. With an innovative approach to big data, analytics and the Internet of Things (IoT), we blend virtual data from software and networks with the huge volume of physical data generated by mobile devices and Internet-connected things to open new worlds of insight. Our unique solutions are helping organizations worldwide improve decision making, increase productivity, and fuel the discoveries of tomorrow. Headquartered in Palo Alto, California, we have regional offices in North America, South America, Europe and the Middle East. Visit www.sysorex.com, follow us @SysorexGlobal and Link up on LinkedIn.

Safe Harbor Statement
All statements in this release that are not based on historical fact are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties and other factors, many of which are outside of the control of Sysorex and its subsidiaries, which could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not limited to, the fluctuation of global economic conditions, the performance of management and employees, the company’s ability to obtain financing, competition, general economic conditions and other factors that are detailed in the company’s periodic and current reports available for review at www.sec.gov. Furthermore, we operate in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise forward-looking statements.

###
Contacts

Media Inquiries:
A. Sage Osterfeld [phone]
[e-mail]

Investor Relations:
CorProminence LLC
Scott Arnold, [phone]
Managing Director
www.corprominence.com

By Sysorex News Desk|November 30th, 2015|Categories: News|Tags: biopharma, deal, IT, q3 2015


http://sysorex.com/2015/11/30/sysorex-announces-latest-in-series-of-it-engagements-with-fortune-500-biopharmaceutical-firm/